Enhertu (Fam-Trastuzumab Deruxtecan-nxki): Benefit–Risk Profile and Clinical Adoption Across Oncology Indications

Mechanism of Action and Pharmacologic Rationale

Fam-trastuzumab deruxtecan-nxki (Enhertu, T-DXd) is a HER2-directed antibody–drug conjugate (ADC) featuring a trastuzumab backbone linked to a potent topoisomerase I inhibitor payload (deruxtecan, an exatecan derivative) via a cleavable tetrapeptide-based linker8. The ADC achieves a high, homogeneous drug-to-antibody ratio of approximately 8—more than twice that of trastuzumab emtansine (T-DM1, ratio ~3.5)—enabling greater cytotoxic delivery per binding event8. Critically, the membrane-permeable payload exhibits a bystander effect, allowing deruxtecan released from HER2-targeted tumor cells to diffuse into neighboring cells, including those with low or heterogeneous HER2 expression715. This structural advantage positions T-DXd as effective across a spectrum of HER2 expression levels and partially explains efficacy in HER2-low disease and trastuzumab-refractory settings.

Dosing is indication-specific: 5.4 mg/kg intravenously every 3 weeks for breast cancer (monotherapy and first-line combination with pertuzumab), HER2-mutant non–small cell lung cancer (NSCLC), and HER2-positive solid tumors; 6.4 mg/kg every 3 weeks for HER2-positive gastric/gastroesophageal junction (GEJ) adenocarcinoma11.

Efficacy Evidence by Indication and Line of Therapy

HER2-Positive Metastatic Breast Cancer

DESTINY-Breast03, the largest randomized trial in this setting, demonstrated sustained superiority of T-DXd over T-DM1 in previously treated HER2-positive metastatic breast cancer. With 43-month median follow-up, T-DXd achieved a median overall survival (OS) of 52.6 months versus 42.7 months with T-DM1 (hazard ratio [HR] 0.73; 95% CI, 0.56–0.94), representing an unprecedented 10-month OS improvement and 27% reduction in death risk1. Median progression-free survival (PFS) was 29.0 months (T-DXd) versus 7.2 months (T-DM1; HR 0.30), with objective response rates (ORR) of 78.9% versus 36.9% and median duration of response (DOR) of 30.5 versus 17.0 months1. The 48-month PFS rate was 41.5% for T-DXd versus 9.9% for T-DM1, and 36-month OS rates were 67.6% versus 55.7%1. This median OS of 52.6 months is among the longest reported in randomized trials of previously treated HER2-positive metastatic breast cancer 1.

In December 2025, the FDA approved T-DXd plus pertuzumab as first-line therapy for unresectable or metastatic HER2-positive breast cancer based on DESTINY-Breast09, which showed median PFS of 40.7 months versus 26.9 months for taxane-trastuzumab-pertuzumab (THP; HR 0.56; p<0.0001), with ORR of 87% versus 81%10.

HER2-Low and HER2-Ultralow Breast Cancer

T-DXd demonstrated groundbreaking efficacy in HER2-low disease (IHC 1+ or IHC 2+/ISH-negative). DESTINY-Breast04 randomized 557 patients (88.7% hormone receptor-positive) to T-DXd or physician's choice chemotherapy. In the HR-positive cohort, T-DXd achieved median PFS of 10.1 versus 5.4 months (HR 0.51; p<0.001) and median OS of 23.9 versus 17.5 months (HR 0.64; p=0.003)5. DESTINY-Breast06 extended these findings to patients receiving T-DXd after endocrine-based therapy (no prior chemotherapy for metastatic disease), demonstrating median PFS of 13.2 versus 8.1 months in the HER2-low population (HR 0.62; p<0.001), with consistent results in the HER2-ultralow exploratory cohort (IHC 0 with membrane staining)6.

HER2-Mutant NSCLC

In DESTINY-Lung02, T-DXd at the approved 5.4 mg/kg dose achieved a 50% confirmed ORR in previously treated HER2-mutant metastatic NSCLC, with median treatment duration of 7.7 months16. DESTINY-Lung01 reported median PFS of 8.2 months and median OS of 17.8 months at the 6.4 mg/kg dose, with responses across HER2 mutation subtypes, including those without HER2 protein expression or amplification17. In a pooled secondary analysis of patients with baseline brain metastases, intracranial confirmed ORR was 50% at 5.4 mg/kg and 30% at 6.4 mg/kg, with 86% and 78% experiencing brain lesion reduction, respectively28.

HER2-Positive Gastric/GEJ Adenocarcinoma

DESTINY-Gastric01 randomized 187 patients with HER2-positive disease progressing after trastuzumab-based therapy to T-DXd 6.4 mg/kg or chemotherapy (irinotecan/paclitaxel). T-DXd achieved ORR of 51% versus 14% (p<0.001), median OS of 12.5 versus 8.4 months (HR 0.59; p=0.01), and median PFS of 5.6 versus 3.5 months (HR 0.47)15.

Table 1. Summary of Pivotal Efficacy Outcomes

Safety Profile: Comprehensive Adverse Event Characterization

Common Adverse Events

In DESTINY-Breast03, any-grade treatment-emergent adverse events (TEAEs) occurred in 99.6% of T-DXd patients versus 95.4% with T-DM1, with Grade ≥3 events in 58.0% versus 52.1%1. Drug-related discontinuations were higher with T-DXd (22.6% vs 7.3%), as were dose reductions (28.0% vs 15.3%) and interruptions (44.0% vs 18.4%)1. In the first-line combination study (T-DXd plus pertuzumab), serious adverse reactions occurred in 27% of patients, with dose interruptions in 69% and reductions in 46%11.

Common TEAEs across breast cancer trials include nausea (67–73%), fatigue (36%), vomiting (38%), alopecia (37%), diarrhea (27%), and decreased appetite211. Hematologic toxicity includes neutropenia (Grade 4: managed per protocol with dose interruption and reduction) and thrombocytopenia11. In gastric cancer at 6.4 mg/kg, the most common Grade ≥3 events were decreased neutrophil count (51%), anemia (38%), and decreased white-cell count (21%)15.

Interstitial Lung Disease: The Boxed Warning

ILD/pneumonitis represents the principal safety concern and is highlighted in the FDA boxed warning11. Incidence varies by dose and population:

Table 2. ILD Incidence and Characteristics

In DESTINY-Breast03 with extended follow-up, adjudicated drug-related ILD/pneumonitis occurred in 16.7% of T-DXd patients (Grade 1: 4.3%, Grade 2: 11.7%, Grade 3: 0.8%; no Grade 4/5 events) versus 3.4% with T-DM11. Cumulative incidence stabilized over time: within 6 months (5.4%), 6–12 months (4.6%), 12–24 months (4.2%), >24 months (2.3%)1. Higher incidence of Grade 1–2 ILD has been observed in patients with moderate renal impairment receiving any dose11.

Management Protocol:

• Grade 1 (asymptomatic): Interrupt until resolved to Grade 0; maintain dose if resolved ≤28 days, reduce one level if >28 days; consider corticosteroids ≥0.5 mg/kg/day prednisolone equivalent11
• Grade ≥2 (symptomatic): Permanently discontinue T-DXd; promptly initiate corticosteroids ≥1 mg/kg/day prednisolone equivalent for ≥14 days followed by gradual taper over ≥4 weeks11

Monitoring requires baseline pulmonary assessment, patient education on respiratory symptoms (cough, dyspnea, fever), and radiographic evaluation for suspected ILD, with consideration of pulmonology consultation11.

Cardiac and Other Toxicities

Left ventricular dysfunction or LVEF decrease occurred in 4.3% of T-DXd patients versus 1.5% with T-DM1 in DESTINY-Breast03, with exposure-adjusted incidence rates of 0.02 per patient-year for both groups1. Treatment has not been studied in patients with baseline LVEF <50% or clinically significant cardiac disease11. LVEF monitoring is required at baseline and regular intervals; permanent discontinuation is mandated for LVEF <40%, symptomatic heart failure, or confirmed LVEF decline >20%11. Embryo-fetal toxicity necessitates effective contraception and pregnancy testing11.

Clinical Positioning and Guideline Recommendations

Breast Cancer

ESMO guidelines recommend T-DXd (ESMO-MCBS score: 4) for HER2-low metastatic breast cancer after one line of chemotherapy [I, A], and may consider T-DXd (ESMO-MCBS score: 3) after ≥2 lines of endocrine therapy or earlier progression scenarios [I, A]12. Sacituzumab govitecan could be considered for HR-positive/HER2-low or -ultralow disease after prior T-DXd [V, B]12. NCCN guidelines for HER2-positive disease incorporate T-DXd as preferred second-line therapy based on DESTINY-Breast03, and now as first-line combination with pertuzumab based on DESTINY-Breast091026.

NSCLC and Gastric Cancer

NCCN guidelines support broad molecular profiling in advanced nonsquamous NSCLC; for tumors with activating HER2 (ERBB2) mutations, trastuzumab deruxtecan is a biomarker-directed treatment option after prior systemic therapy 13. For gastric cancer, universal HER2 testing is recommended at diagnosis if advanced/metastatic disease is documented or suspected14.

Patient Selection and Diagnostic Considerations

HER2 testing paradigms are indication-specific. In breast cancer, HER2-positive is defined as IHC 3+ or IHC 2+/ISH-positive, while HER2-low comprises IHC 1+ or IHC 2+/ISH-negative, and HER2-ultralow includes IHC 0 with membrane staining69. In NSCLC, HER2 (ERBB2) mutation detection via next-generation sequencing (NGS) panels—tissue or ctDNA—is essential; responses in DESTINY-Lung01 were observed across mutation subtypes, including those without protein expression or amplification1720. In gastric cancer, HER2-positive status requires IHC 3+ or IHC 2+/ISH-positive915.

Real-world data confirm efficacy in challenging subgroups. In a multicenter study of HER2-positive/low metastatic breast cancer with active brain metastases, T-DXd achieved intracranial ORR of 65.5% (HER2-positive) and 66.7% (HER2-low), with 12-month intracranial PFS rates of 79.8% and 51.9%, respectively27.

Health System and Practical Considerations

Cost-effectiveness analyses reveal challenges. A 2025 Spanish evaluation estimated incremental cost-utility ratios of €648,710/QALY (overall population) and €541,758/QALY (HR+ subgroup) for HER2-low breast cancer, far exceeding typical willingness-to-pay thresholds22. T-DXd achieved China NRDL approval in January 2025 (with ~63% discount) across HER2-positive/low breast, gastric, and HER2-mutant NSCLC indications23, while NICE terminated UK appraisal for HER2-low breast cancer due to absence of manufacturer submission24.

Infusion workflows require standard premedication, complete blood count monitoring before each dose, and comprehensive pulmonary symptom surveillance11. Dose modification schedules are codified: for 5.4 mg/kg, reduce to 4.4 mg/kg, then 3.2 mg/kg; for 6.4 mg/kg, reduce to 5.4 mg/kg, then 4.4 mg/kg11.

Future Outlook and Resistance Mechanisms

Mechanisms of resistance to trastuzumab deruxtecan remain an active area of investigation; potential contributors reported across preclinical and translational studies include reduced HER2 expression, alterations affecting payload sensitivity, and drug-efflux pathways. ABCC1 expression emerged as an independent predictor of T-DXd OS, stratifying outcomes within HER2 categories; ABCC1 inhibition with MK-571 restored T-DXd sensitivity in resistant cell lines18. These insights inform rational combination strategies and next-generation ADC development.

Conclusion

Enhertu demonstrates transformative efficacy across HER2-positive and HER2-low malignancies, achieving unprecedented survival in HER2-positive breast cancer (52.6-month median OS) and establishing HER2-low as a viable therapeutic target. The principal safety concern—ILD/pneumonitis (10–17% incidence, 0.5–0.9% fatal)—is manageable through vigilant monitoring and permanent discontinuation at Grade ≥2. Clinical adoption is supported by robust guideline endorsement and regulatory approvals, though cost-effectiveness remains a barrier in resource-constrained settings. Comprehensive molecular testing, risk-benefit stratification by line of therapy, and adherence to ILD management algorithms are essential for optimal patient outcomes.